HIGHLIGHTS – Syphilis Quarterly Report 2025-Q3

October 28, 2025



In 2025-Q3, 332 infectious syphilis cases were recorded in BC. Syphilis rate¹ remains at a historical high but has decreased by ↓31.8% vs 2024-Q3.

Key Populations

Congenital Syphilis

Cases of females ages 15-49 continued to decline for the third quarter in a row (Q1 n=147, Q2 n=136, Q3 n=102.)

Congenital syphilis is a significant public health concern. Two cases were reported in Q3, down from a high of eight cases in Q1 and three in Q2.

Testing Episode Volumes

Regional Trends

78,362 testing episodes⁴ were reported in 2025-Q3, which is a ↑5% change compared to 2024-Q3.

2025 Q3 saw the fewest cases since 2021 Q2. Island and Interior remain stable over 2025. All other regions recorded a third straight quarter of decline.

Demographics Northern Health has highest rate per 100K in 2025-Q3

Regional rate¹ 2025-Q3: 9.4 NH, 8 VCH, 6.7 ISLH, 4.4 IH, 4.1 FH

%Rate change (vs 2024-Q3): \[\preceq 15.2\% ISLH, \preceq 24.1\% FH, \preceq 26.7\% IH, \preceq 38.5\% VCH, \preceq 54.1\% NH

Highest rates¹ in 2025-Q3 were among females aged 30-39 (4.5/100k) and males aged 30-39 (7.4/100K)

Sex/Gender (%cases 2025-Q3): 66.3% Male (62.1% in 2024-Q3), 33.1% Female (37% in 2024-Q3)

0.3% Transgender (0.2% in 2024-Q3), -% X (0.2% in 2024-Q3)

Age group (rate¹ 2025-Q3): <15 years: -, 15-19 years: 2.4, 20-24 years: 8.6, 25-29 years: 9.2

30-39 years: 12.1, 40-59 years: 8.4, 60+ years: 1.4

Gender of Partner² 154 cases had gender of partner information in 2025-Q3

%WSM has decreased compared to 2024-Q3:
%MSW has decreased compared to 2024-Q3:
%gbMSM has increased compared to 2024-Q3:
41.6% gbMSM in 2025-Q3 vs 34.5% in 2024-Q3
41.6% gbMSM in 2025-Q3 vs 35.3% in 2024-Q3

Severe Outcomes Highlighting cases linked to pregnancy and extra-genital manifestations

Maternal Syphilis prenatal screening caught 5.9% of 2025-Q3 female cases aged 15-49

Congenital Syphilis³ 2 cases in 2025-Q3, 175% vs 2024-Q3 (8 cases)

14 syphilitic stillbirths and early neonatal losses (within 7-days of live birth) have been reported since 2019

Ocular & Neurosyphilis³ 3.6% of 2025-Q3 vs 2.9% of 2024-Q3 cases

Time to Treatment (Tx) 261 cases had time to Tx information in 2025-Q3

Time interval (time from syphilis diagnosis to treatment initiation):

Females experience longer time to Tx than males: within one-week 65.2% Male / 59.3% Female Majority receives Tx within 30-days: within 30-days 96.1% Male / 97.5% Female MSW experience longer time to Tx than gbMSM: within one-week 54.5% MSW / 75% gbMSM

Tx Completion 95% of cases started and 78% completed Tx in 2025-Q1

Tx completion is reported with a two-quarter lag to allow sufficient time for follow-up

%Tx not started is higher in females than males: 2.1% Male / 9.4% Female of 2025-Q1 cases

¹rate: cases per 100,000 population, ²Gender of Partner information updates over time, interpret historical comparison with caution. Gender of Partner categories: MSW - Men who report having sex with women only; WSM - Women who report having sex with men only, gbMSM – gay, bisexual or other men who have sex with men, for other gender of partner categories refer to <u>full report</u>, ³defined in <u>BC case definitions</u>, ⁴one episode represents a 30-day testing window. <u>Data Note</u>: Case data are sourced from Intrahealth Profile EMR. Testing episodes are sourced from STIBBI Mart.